HC Wainwright Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $15.00

Lexeo Therapeutics (NASDAQ:LXEO) had its target price dropped by analysts at HC Wainwright from $23.00 to $15.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 362.96% from the stock’s previous close. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q1 2026 earnings at ($0.62) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.54) EPS.

Several other equities analysts have also commented on LXEO. Royal Bank of Canada decreased their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th. Finally, Chardan Capital reduced their price target on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $20.20.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $3.24 on Friday. The firm has a market capitalization of $107.56 million, a P/E ratio of -1.03 and a beta of 1.27. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $3.07 and a 200 day moving average price of $4.94. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). Sell-side analysts expect that Lexeo Therapeutics will post -3.14 EPS for the current year.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors have recently made changes to their positions in the company. Barclays PLC increased its holdings in shares of Lexeo Therapeutics by 162.2% during the 3rd quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after purchasing an additional 31,057 shares in the last quarter. Wellington Management Group LLP grew its stake in Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock valued at $507,000 after acquiring an additional 25,089 shares during the period. Rhumbline Advisers grew its stake in Lexeo Therapeutics by 19.6% in the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock valued at $166,000 after acquiring an additional 4,127 shares during the period. JPMorgan Chase & Co. grew its stake in Lexeo Therapeutics by 135.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock valued at $93,000 after acquiring an additional 5,915 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Lexeo Therapeutics in the 4th quarter valued at $117,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.